MQS Management LLC Purchases Shares of 728 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

MQS Management LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 728 shares of the biopharmaceutical company's stock, valued at approximately $765,000.

Other hedge funds have also recently added to or reduced their stakes in the company. SteelPeak Wealth LLC lifted its position in Regeneron Pharmaceuticals by 173.0% in the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company's stock valued at $1,148,000 after acquiring an additional 692 shares in the last quarter. Atria Investments Inc increased its stake in Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company's stock worth $8,317,000 after buying an additional 941 shares in the last quarter. Tri Locum Partners LP lifted its position in Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company's stock worth $18,410,000 after buying an additional 8,949 shares during the last quarter. Tidal Investments LLC increased its stake in shares of Regeneron Pharmaceuticals by 16.8% during the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company's stock valued at $4,774,000 after buying an additional 711 shares during the period. Finally, Sanctuary Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $47,611,000. Institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on REGN shares. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a report on Thursday, October 24th. Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Evercore ISI cut their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Finally, Leerink Partners reiterated a "market perform" rating and issued a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $1,107.25.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm's stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 7.48% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded down $16.67 during trading on Wednesday, reaching $804.33. 587,965 shares of the stock were exchanged, compared to its average volume of 524,084. Regeneron Pharmaceuticals, Inc. has a twelve month low of $784.96 and a twelve month high of $1,211.20. The company has a market capitalization of $88.39 billion, a P/E ratio of 20.09, a price-to-earnings-growth ratio of 3.10 and a beta of 0.15. The stock has a 50 day simple moving average of $1,007.57 and a 200-day simple moving average of $1,037.30. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.